Related Experiment Video

Updated: Apr 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

The Health Impact Fund: how might it work for novel anticoagulants in atrial fibrillation?

Amitava Banerjee1, Thomas Pogge2

  • 1Centre for Cardiovascular Sciences, College of Medical and Dental Sciences, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK.

Global Heart
|February 11, 2015
PubMed

Insights

The Health Impact Fund rewards pharmaceutical companies for the health impact of new drugs, like novel anticoagulants for atrial fibrillation stroke prevention. This approach could benefit patients and governments by improving drug development and healthcare outcomes.

Area of Science:

  • Pharmacoeconomics
  • Public Health
  • Drug Development

Background:

  • Cardiovascular diseases (CVDs) are a leading global health burden, incurring high healthcare costs, primarily for pharmaceuticals.
  • Pharmaceutical spending on CVDs significantly impacts health systems, society, and the pharmaceutical industry.
  • Novel anticoagulants offer improved prevention of stroke and thromboembolism in atrial fibrillation.

Purpose of the Study:

  • To introduce and illustrate the Health Impact Fund (HIF) concept.
  • To explore the application of HIF using novel anticoagulants for atrial fibrillation.
  • To demonstrate how epidemiological data and modeling can predict drug health impact.

Main Methods:

  • Review of existing data on novel anticoagulants and atrial fibrillation.
  • Analysis of current healthcare spending on cardiovascular drugs.
  • Application of epidemiological data and disease modeling techniques.

Main Results:

  • The Health Impact Fund offers a novel incentive mechanism for pharmaceutical innovation.
  • Predictive modeling using epidemiological data can estimate the future health impact of new drugs.
  • Novel anticoagulants show significant potential for reducing stroke and thromboembolism in atrial fibrillation patients.

Conclusions:

  • The Health Impact Fund presents a promising model for aligning pharmaceutical rewards with public health goals.
  • This mechanism could incentivize the development of drugs addressing significant disease burdens like CVDs.
  • Further investigation into the Health Impact Fund is warranted due to its potential benefits for pharmaceutical companies, patients, and governments.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

14.0K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
623
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613